Company / CIK 0001919246
Pelthos Therapeutics Inc.
- Ticker
- PTHS
- Size, estimated from filings
- Micro cap (under $300M)
- Insiders on file
- 8
- Federal contracts on record
- none matched
- Lobbying filings on record
- none matched
- SEC filings
- EDGAR ↗
- Latest trade on record
- October 2, 2026
Pelthos Therapeutics Inc. (PTHS) has 8 insiders on file who disclosed 39 transactions in the last 12 months (2 open-market buys, 26 sales, about $1.5M at reported prices). No federal contract award that started in the last 180 days was found for a recipient with exactly this name; no lobbying filing names it as client this year.
Pelthos Therapeutics Inc. in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
6 people account for the disclosed buying and selling in Pelthos Therapeutics Inc. over the last 12 months; the most active is Davis Todd C with $1000K.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| Friedberg Ezra M | Director | 12 | 0 | 12 | October 6, 2026 |
| Pauls Matthew | Director | 10 | 0 | 5 | October 6, 2026 |
| Greenleaf Peter | Director | 5 | 0 | 5 | October 6, 2026 |
| Davis Todd C | Chief Executive Officer | 2 | 2 | 0 | July 6, 2026 |
| Francis Knuettel II | CFO, Treas & Secty | 4 | 0 | 2 | May 26, 2026 |
| Malamut Richard | Director | 2 | 0 | 2 | April 6, 2026 |
| Einhorn Andrew J. | Director | 1 | 0 | 0 | December 29, 2025 |
| LIGAND PHARMACEUTICALS INC | Director | 3 | 0 | 0 | December 19, 2025 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pauls Matthew | PTHS | Sell S | October 2, 2026 | October 6, 2026 | 4d | 786 | $21 | $17K | 10b5-1 plan | Form 4 ↗ | |
| Friedberg Ezra M | PTHS | Sell S | October 2, 2026 | October 6, 2026 | 4d | 558 | $21 | $12K | 10b5-1 plan | Form 4 ↗ | |
| Greenleaf Peter | PTHS | Sell S | October 2, 2026 | October 6, 2026 | 4d | 797 | $21 | $17K | 10b5-1 plan | Form 4 ↗ | |
| Friedberg Ezra M | PTHS | Sell S | July 2, 2026 | July 7, 2026 | 5d | 24 | $27 | $656 | late10b5-1 plan | Form 4 ↗ | |
| Friedberg Ezra M | PTHS | Sell S | July 2, 2026 | July 7, 2026 | 5d | 534 | $26 | $14K | late10b5-1 plan | Form 4 ↗ | |
| Pauls Matthew | PTHS | Sell S | July 2, 2026 | July 7, 2026 | 5d | 94 | $27 | $2,572 | late10b5-1 plan | Form 4 ↗ | |
| Pauls Matthew | PTHS | Sell S | July 2, 2026 | July 7, 2026 | 5d | 692 | $26 | $18K | late10b5-1 plan | Form 4 ↗ | |
| Greenleaf Peter | PTHS | Sell S | July 2, 2026 | July 7, 2026 | 5d | 85 | $27 | $2,318 | late10b5-1 plan | Form 4 ↗ | |
| Greenleaf Peter | PTHS | Sell S | July 2, 2026 | July 7, 2026 | 5d | 712 | $26 | $19K | late10b5-1 plan | Form 4 ↗ | |
| Friedberg Ezra M | PTHS | Sell S | June 15, 2026 | June 17, 2026 | 2d | 59 | $28 | $1,648 | 10b5-1 plan | Form 4 ↗ | |
| Friedberg Ezra M | PTHS | Sell S | June 15, 2026 | June 17, 2026 | 2d | 224 | $27 | $6,076 | 10b5-1 plan | Form 4 ↗ | |
| Davis Todd C | PTHS | Buy P | June 11, 2026 | June 15, 2026 | 4d | 503 | $29 | $14K | Form 4 ↗ | ||
| Davis Todd C | PTHS | Buy P | June 11, 2026 | June 15, 2026 | 4d | 35,445 | $28 | $986K | Form 4 ↗ | ||
| Francis Knuettel II | PTHS | Option / conversion D | May 22, 2026 | May 26, 2026 | 4d | 42,500 | — | — | derivative | Form 4 ↗ | |
| Francis Knuettel II | PTHS | Other A | May 22, 2026 | May 26, 2026 | 4d | 59,500 | — | — | derivative | Form 4 ↗ | |
| Francis Knuettel II | PTHS | Sell S | May 22, 2026 | May 26, 2026 | 4d | 1,500 | $27 | $40K | indirect | Form 4 ↗ | |
| Francis Knuettel II | PTHS | Sell D | May 22, 2026 | May 26, 2026 | 4d | 13,947 | — | — | Form 4 ↗ | ||
| Friedberg Ezra M | PTHS | Sell F | May 14, 2026 | May 18, 2026 | 4d | 144 | $27 | $3,889 | 10b5-1 plan | Form 4 ↗ | |
| Malamut Richard | PTHS | Sell S | April 2, 2026 | April 6, 2026 | 4d | 280 | $21 | $5,981 | 10b5-1 plan | Form 4 ↗ | |
| Malamut Richard | PTHS | Sell S | April 2, 2026 | April 6, 2026 | 4d | 310 | $21 | $6,359 | 10b5-1 plan | Form 4 ↗ | |
| Friedberg Ezra M | PTHS | Sell S | April 2, 2026 | April 6, 2026 | 4d | 265 | $21 | $5,661 | 10b5-1 plan | Form 4 ↗ | |
| Friedberg Ezra M | PTHS | Sell S | April 2, 2026 | April 6, 2026 | 4d | 293 | $21 | $6,010 | 10b5-1 plan | Form 4 ↗ | |
| Pauls Matthew | PTHS | Sell S | April 2, 2026 | April 6, 2026 | 4d | 371 | $21 | $7,926 | 10b5-1 plan | Form 4 ↗ | |
| Pauls Matthew | PTHS | Sell S | April 2, 2026 | April 6, 2026 | 4d | 415 | $21 | $8,514 | 10b5-1 plan | Form 4 ↗ | |
| Greenleaf Peter | PTHS | Sell S | April 2, 2026 | April 6, 2026 | 4d | 377 | $21 | $8,053 | 10b5-1 plan | Form 4 ↗ | |
| Greenleaf Peter | PTHS | Sell S | April 2, 2026 | April 6, 2026 | 4d | 420 | $21 | $8,616 | 10b5-1 plan | Form 4 ↗ | |
| Einhorn Andrew J. | PTHS | Other A | December 23, 2025 | December 29, 2025 | 6d | 12,000 | — | — | late | Form 4 ↗ | |
| LIGAND PHARMACEUTICALS INC | PTHS | Other A | December 17, 2025 | December 19, 2025 | 2d | — | — | — | derivative | Form 4 ↗ | |
| LIGAND PHARMACEUTICALS INC | PTHS | Option / conversion D | December 17, 2025 | December 19, 2025 | 2d | — | — | — | derivative | Form 4 ↗ | |
| Pauls Matthew | PTHS | Option / conversion M | October 2, 2025 | December 12, 2025 | 71d | 2,123 | — | — | latederivative | Form 4 ↗ | |
| Pauls Matthew | PTHS | Option / conversion M | July 2, 2025 | December 12, 2025 | 163d | 8,493 | — | — | latederivative | Form 4 ↗ | |
| Pauls Matthew | PTHS | Other G | December 10, 2025 | December 12, 2025 | 2d | 9,542 | — | — | Form 4 ↗ | ||
| Pauls Matthew | PTHS | Option / conversion M | October 2, 2025 | December 12, 2025 | 71d | 2,123 | — | — | late | Form 4 ↗ | |
| Pauls Matthew | PTHS | Option / conversion M | July 2, 2025 | December 12, 2025 | 163d | 8,493 | — | — | late | Form 4 ↗ | |
| Friedberg Ezra M | PTHS | Sell S | November 25, 2025 | November 26, 2025 | 1d | 2,000 | $28 | $56K | indirect | Form 4 ↗ | |
| Friedberg Ezra M | PTHS | Sell S | November 25, 2025 | November 26, 2025 | 1d | 1 | $29 | $29 | indirect | Form 4 ↗ | |
| Friedberg Ezra M | PTHS | Sell S | November 25, 2025 | November 26, 2025 | 1d | 2,000 | $28 | $56K | indirect | Form 4 ↗ | |
| Friedberg Ezra M | PTHS | Sell S | November 25, 2025 | November 26, 2025 | 1d | 5,999 | $28 | $168K | indirect | Form 4 ↗ | |
| LIGAND PHARMACEUTICALS INC | PTHS | Other A | November 6, 2025 | November 10, 2025 | 4d | — | $9,000,000 | — | derivative | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "Pelthos Therapeutics Inc.". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
No LDA filing posted since October 2025 names "Pelthos Therapeutics Inc." as the client. Filings under a subsidiary or trade-association name are not matched — search lobbying.
Related companies
Companies whose stock was traded by the same people who traded PTHS, by number of filers in common. It shows overlap in public filings and nothing else.
- LIGAND PHARMACEUTICALS INC LGND 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 19 | 39 | November 10, 2025 | October 6, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.